Form 4: Century Therapeutics CEO Sells Shares to Cover Tax Obligations

Century Therapeutics CEO, Brent Pfeiffenberger, sold 243,447 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Brent Pfeiffenberger, the President and CEO of Century Therapeutics, Inc., sold 243,447 shares of common stock on December 4, 2024.
• The sale was executed at a price of $1.44 per share.
• This transaction was to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Pfeiffenberger directly owns 1,227,257 shares of Century Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document describes a routine transaction for tax purposes, which is neither positive nor negative for the company's overall outlook.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the industry.
• Many companies use restricted stock units as part of executive compensation packages, leading to similar tax-related sales.
• The sale of 243,447 shares is not unusual for a CEO of a company of this size.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale for tax purposes.

Key Dates

Keywords

Century Therapeutics, Brent Pfeiffenberger, stock sale, tax obligations, restricted stock units, insider trading, IPSC